Market Access Impact: Ulcerative Colitis (US) 2018
Market barriers affect 15% of ulcerative colitis prescriptions. Is your brand losing out?
In the US, where market barriers affect 15% of all ulcerative colitis prescriptions, the top two brands have a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Ulcerative Colitis (US) .
Based on a survey of 100 gastroenterologists, the report covers 6 major therapies from Takeda, AbbVie, Merck & Co., Pfizer and Janssen Biotech. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Reasons to Purchase
Barriers affect 15% of all prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
Two brands see significant share increases: 2 brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the brand in 2nd place.
One brands sees a significant loss: Despite being prescribed by over 90% of physicians, one brand loses over 4% of their market share because of barriers. Why? And can this be prevented?
Eliminating barriers would close the gap at the top: The leading brand relies on other brands losing out. Removing these barriers would have an impact on market share for two leading brands. Are they yours, or one of your competitors?
One brand has a perception problem: Nearly 10% of surveyed doctors would not prescribe a specific brand, leaving other brands to capture market share.
Insight into 6 Major Ulcerative Colitis Drugs
Entyvio (vedolizumab, Takeda)
Humira (adalimumab; AbbVie)
Renflexis (infliximab-abda; Merck & Co.)
Inflectra (infliximab-dyyb; Pfizer)
Remicade (infliximab; Janssen Biotech)
Simponi (golimumab; Janssen Biotech)
Exploring Market Access Barriers
Market Access Impact: Ulcerative Colitis (US)  explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US-based gastroenterologists, chosen from the largest community of validated physicians in the world.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with Ulcerative Colitis in total in the last month
We conducted the survey between February 6-12, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook